Patrick R.  O'Neil net worth and biography

Patrick O'Neil Biography and Net Worth

Mr. O’Neil is the Chief Legal Officer and General Counsel of Ionis Pharmaceuticals. He is responsible for managing the legal, patent and GCP QA/QC departments. Mr. O’Neil also serves as Ionis’ corporate secretary. Mr. O’Neil joined Ionis in October 2001.

Prior to joining Ionis, Mr. O’Neil was an associate at Cooley LLP.

Mr. O’Neil received his BS in Business Administration, Finance Concentration from the University of San Francisco and his J.D. at UC Davis School of Law.

What is Patrick R. O'Neil's net worth?

The estimated net worth of Patrick R. O'Neil is at least $2.09 million as of January 25th, 2024. Mr. O'Neil owns 46,802 shares of Ionis Pharmaceuticals stock worth more than $2,090,177 as of March 28th. This net worth evaluation does not reflect any other investments that Mr. O'Neil may own. Learn More about Patrick R. O'Neil's net worth.

How do I contact Patrick R. O'Neil?

The corporate mailing address for Mr. O'Neil and other Ionis Pharmaceuticals executives is 2855 GAZELLE COURT, CARLSBAD CA, 92010. Ionis Pharmaceuticals can also be reached via phone at (760) 931-9200 and via email at [email protected]. Learn More on Patrick R. O'Neil's contact information.

Has Patrick R. O'Neil been buying or selling shares of Ionis Pharmaceuticals?

During the past quarter, Patrick R. O'Neil has sold $333,787.50 in shares of Ionis Pharmaceuticals stock. Most recently, Patrick R. O'neil sold 6,450 shares of the business's stock in a transaction on Thursday, January 25th. The shares were sold at an average price of $51.75, for a transaction totalling $333,787.50. Following the completion of the sale, the executive vice president now directly owns 46,802 shares of the company's stock, valued at $2,422,003.50. Learn More on Patrick R. O'Neil's trading history.

Who are Ionis Pharmaceuticals' active insiders?

Ionis Pharmaceuticals' insider roster includes C. Bennett (EVP), Spencer Berthelsen (Director), Brian Birchler (EVP), Onaiza Cadoret-Manier (EVP), Breaux Castleman (Director), Stanley Crooke (Chairman), Allene Diaz (Director), Richard Geary (EVP), Elizabeth Hougen (CFO), Joseph Klein, III (Director), Brett Monia (CEO), Frederick Muto (Director), Patrick O'Neil (EVP), B. Parshall, Esq. (Director), Eugene Schneider (EVP), and Eric Swayze (EVP). Learn More on Ionis Pharmaceuticals' active insiders.

Are insiders buying or selling shares of Ionis Pharmaceuticals?

During the last year, insiders at the sold shares 28 times. They sold a total of 288,471 shares worth more than $14,210,660.41. The most recent insider tranaction occured on February, 16th when CEO Brett P Monia sold 387 shares worth more than $17,217.63. Insiders at Ionis Pharmaceuticals own 2.7% of the company. Learn More about insider trades at Ionis Pharmaceuticals.

Information on this page was last updated on 2/16/2024.

Patrick R. O'Neil Insider Trading History at Ionis Pharmaceuticals

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
1/25/2024Sell6,450$51.75$333,787.5046,802View SEC Filing Icon  
12/26/2023Sell20,825$51.46$1,071,654.5040,355View SEC Filing Icon  
5/24/2023Sell1,527$41.70$63,675.9040,355View SEC Filing Icon  
1/30/2023Sell4,500$39.42$177,390.0044,179View SEC Filing Icon  
4/12/2022Sell6,792$40.06$272,087.5234,536View SEC Filing Icon  
1/25/2021Sell5,324$63.50$338,074.0026,502View SEC Filing Icon  
2/10/2020Sell3,882$59.60$231,367.2020,720View SEC Filing Icon  
4/5/2019Sell49,528$83.99$4,159,856.7227,327View SEC Filing Icon  
4/3/2019Sell7,654$84.83$649,288.8227,327View SEC Filing Icon  
3/18/2019Sell28,800$78.79$2,269,152.0048,473View SEC Filing Icon  
2/27/2019Sell26,800$68.01$1,822,668.0024,373View SEC Filing Icon  
2/5/2019Sell19,600$59.25$1,161,300.0023,673View SEC Filing Icon  
1/3/2019Sell4,400$54.80$241,120.0014,584View SEC Filing Icon  
3/12/2018Sell1,000$55.00$55,000.0015,452View SEC Filing Icon  
1/29/2018Sell355$55.00$19,525.0014,507View SEC Filing Icon  
1/25/2018Sell645$55.00$35,475.0015,097View SEC Filing Icon  
12/1/2017Sell1,000$55.50$55,500.0011,433View SEC Filing Icon  
11/1/2017Sell1,000$58.35$58,350.0011,433View SEC Filing Icon  
10/5/2017Sell1,000$55.00$55,000.00View SEC Filing Icon  
9/6/2017Sell1,000$55.00$55,000.0010,633View SEC Filing Icon  
6/1/2017Sell70$48.00$3,360.0010,369View SEC Filing Icon  
5/1/2017Sell650$48.75$31,687.5010,299View SEC Filing Icon  
4/24/2017Sell500$45.00$22,500.0010,523View SEC Filing Icon  
4/12/2017Sell1,000$40.07$40,070.0010,449View SEC Filing Icon  
3/1/2017Sell1,500$49.29$73,935.0012,949View SEC Filing Icon  
2/6/2017Sell1,500$46.17$69,255.0012,449View SEC Filing Icon  
12/5/2016Sell350$45.00$15,750.009,876View SEC Filing Icon  
11/14/2016Sell1,000$45.00$45,000.009,720View SEC Filing Icon  
4/6/2016Sell1,000$45.00$45,000.0010,124View SEC Filing Icon  
3/23/2016Sell1,000$45.40$45,400.0010,124View SEC Filing Icon  
12/1/2015Sell1,000$61.50$61,500.006,259View SEC Filing Icon  
11/3/2015Sell1,000$51.95$51,950.006,259View SEC Filing Icon  
3/19/2015Sell30,525$74.85$2,284,796.25View SEC Filing Icon  
1/2/2015Sell1,500$62.12$93,180.00View SEC Filing Icon  
12/1/2014Sell1,500$51.21$76,815.00View SEC Filing Icon  
11/3/2014Sell1,500$46.17$69,255.00View SEC Filing Icon  
10/1/2014Sell1,500$38.04$57,060.00View SEC Filing Icon  
8/12/2014Sell1,500$35.00$52,500.00View SEC Filing Icon  
7/1/2014Sell1,500$35.33$52,995.00View SEC Filing Icon  
9/4/2013Sell2,500$27.09$67,725.00View SEC Filing Icon  
See Full Table

Patrick R. O'Neil Buying and Selling Activity at Ionis Pharmaceuticals

This chart shows Patrick R O'neil's buying and selling at Ionis Pharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Ionis Pharmaceuticals Company Overview

Ionis Pharmaceuticals logo
Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of ATTR; Olezarsen for patients with FCS and severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Tofersen to inhibit the production of superoxide dismutase 1; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus. In addition, the company develops IONIS-FB-LRx to inhibit the production of complement factor B and the alternative complement pathway; and ION224 to reduce the production of diacylglycerol acyltransferase 2. It has a strategic collaboration with Biogen for the treatment of neurological disorders; and collaboration and license agreement with Metagenomi, Inc, AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis, Roche, Swedish Orphan Biovitrum AB, and PTC Therapeutics. The company was incorporated in 1989 and is based in Carlsbad, California.
Read More

Today's Range

Now: $44.66
Low: $43.83
High: $44.85

50 Day Range

MA: $46.70
Low: $42.03
High: $52.01

2 Week Range

Now: $44.66
Low: $33.32
High: $54.44

Volume

868,087 shs

Average Volume

1,008,900 shs

Market Capitalization

$6.51 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.4